-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
Vapendavir
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/439085-51-5.gif)
| Category | Enterovirus (EV) |
| CAS | 439085-51-5 |
| Description | Vapendavir is an orally active capsid-binding inhibitor as a capsid binderwith potent anti-rhinoviral activity and broad serotype coverage. |
Product Information
| Synonyms | Vapendavir; BTA-798; BTA798; BTA 7983-Ethoxy-6-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]-1,2-benzisoxazole; |
| IUPAC Name | 3-ethoxy-6-[2-[1-(6-methylpyridazin-3-yl)piperidin-4-yl]ethoxy]-1,2-benzoxazole |
| Molecular Weight | 382.46 |
| Molecular Formula | C21H26N4O3 |
| Canonical SMILES | CCOc1c2ccc(cc2on1)OCCC3CCN(CC3)c4ccc(nn4)C |
| InChI | 1S/C21H26N4O3/c1-3-26-21-18-6-5-17(14-19(18)28-24-21)27-13-10-16-8-11-25(12-9-16)20-7-4-15(2)22-23-20/h4-7,14,16H,3,8-13H2,1-2H3 |
| InChIKey | DKSVBVKHUICELN-UHFFFAOYSA-N |
| Purity | ≥95% |
| Solubility | Soluble in DMSO |
| Appearance | White Solid |
| Application | Rhinovirus replication inhibitor |
| Shelf Life | As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly. |
| Storage | Store at -20 °C |
| Complexity | 475 |
| Exact Mass | 382.20049070 |
| In Vitro | Vapendavir (BTA798) efficiently inhibit the in vitro replication of 21 EV71 strains/isolates that are representative of the different genogroups A, B, and C. |
| PSA | 73.51000 |
| Target | EC50: 0.5-1.4 μM (EV71 strains) |
| XLogP3-AA | 3.9 |
